MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

6.32 -6.23

Overview

Share price change

24h

Current

Min

6.25

Max

7

Key metrics

By Trading Economics

Income

31M

-172M

Sales

4.4M

19M

Profit margin

-899.843

Employees

800

EBITDA

44M

-148M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-12.37% downside

Market Stats

By TradingEconomics

Market Cap

-138M

2.4B

Previous open

12.55

Previous close

6.32

News Sentiment

By Acuity

21%

79%

42 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 paź 2025, 21:10 UTC

Major Market Movers

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 paź 2025, 19:03 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 paź 2025, 17:58 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 paź 2025, 17:12 UTC

Earnings

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 paź 2025, 17:12 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 paź 2025, 16:59 UTC

Acquisitions, Mergers, Takeovers

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 paź 2025, 23:44 UTC

Market Talk

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 paź 2025, 23:42 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 paź 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

16 paź 2025, 22:15 UTC

Earnings

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 paź 2025, 22:15 UTC

Earnings

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 paź 2025, 22:15 UTC

Earnings

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 paź 2025, 22:02 UTC

Market Talk

Global Equities Roundup: Market Talk

16 paź 2025, 22:02 UTC

Market Talk

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 paź 2025, 20:50 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

16 paź 2025, 20:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 paź 2025, 20:23 UTC

Market Talk

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 paź 2025, 20:20 UTC

Earnings

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 paź 2025, 20:08 UTC

Acquisitions, Mergers, Takeovers

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 paź 2025, 19:37 UTC

Acquisitions, Mergers, Takeovers

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 paź 2025, 19:26 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 paź 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 paź 2025, 19:23 UTC

Market Talk

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 paź 2025, 19:23 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 paź 2025, 18:35 UTC

Market Talk
Earnings

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 paź 2025, 18:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 paź 2025, 18:31 UTC

Market Talk

Global Equities Roundup: Market Talk

16 paź 2025, 18:31 UTC

Market Talk

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 paź 2025, 16:57 UTC

Market Talk

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

-12.37% downside

12 Months Forecast

Average 5.95 USD  -12.37%

High 8 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

42 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat